Super-Resolution ultrasound could spot kidney disease without a needle

NCT ID NCT05764642

ENROLLING_BY_INVITATION Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new ultrasound technique called super-resolution ultrasound imaging (SRUI) to see tiny blood vessels in the kidneys. Researchers will give an FDA-approved contrast agent called Definity to healthy volunteers and people with chronic kidney disease (CKD) who need a kidney biopsy. The goal is to see if SRUI can measure blood vessel health and help diagnose CKD without invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Definity (ultrasound contrast agent)
What this could lead to: If successful, this imaging technique could help doctors diagnose and monitor chronic kidney disease more accurately and less invasively.
What could go wrong: This is a Phase 2 study with only 186 participants, so results are preliminary. The imaging may not prove reliable enough to replace standard tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES HEALTHY

Contacts and locations

Locations

Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Mayo Clinic Minnesota

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.